Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials
Kardiovaskuläre und renale Endpunkte sowie Mortalität unter langwirksamen injizierbaren und oralen GLP-1-Rezeptoragonisten bei Typ-2-Diabetes: systematische Übersicht und Metaanalyse randomisierter Studien
Diabetes Care · 29.03.2025
DOI: 10.2337/dc25-0241 ↗Auf einen Blick
Eine Metaanalyse von 10 Studien zeigt: Langwirksame GLP-1-Rezeptoragonisten senkten bei Typ-2-Diabetes MACE, Herzinsuffizienz-Hospitalisationen, renale Endpunkte und die Gesamtmortalität. Der Effekt war unabhängig vom Applikationsweg.
Fragestellung
Verbessern langwirksame GLP-1-Rezeptoragonisten bei Typ-2-Diabetes kardiovaskuläre, renale und Mortalitätsendpunkte, und unterscheiden sich subkutane und orale Formen?
Methode
Systematische Übersichtsarbeit von PubMed bis 7. Februar 2025; randomisierte placebokontrollierte CV- und Nieren-Endpunktstudien mit ≥500 Personen mit T2D; random-effects-Metaanalyse.
Ergebnisse
10 Studien mit n = 71.351. MACE: HR 0,86 (95 %-KI 0,81–0,90; I2 = 27,6 %), HHF: 0,86 (0,79–0,93; I2 = 2,1 %), kombinierter renaler Endpunkt: 0,83 (0,75–0,92; I2 = 20,4 %), Gesamtmortalität: 0,88 (0,82–0,93; I2 = 17,5 %).
Einschränkungen
Studienebene-Metaanalysen erlauben keine detaillierten Subgruppenanalysen und können ökologischen Bias einführen.
Schlussfolgerung der Autor:innen
Nach Einschätzung der Autor:innen senken langwirksame GLP-1-Rezeptoragonisten, einschließlich injizierbarer und oraler Formen, MACE, HHF, renale Ereignisse und die Gesamtmortalität bei T2D.
Kernaussagen
- MACE reduziert: HR 0,86 (95 %-KI 0,81–0,90)
- Kein signifikanter Unterschied nach Applikationsweg
- Keine erhöhten Risiken für schwere Hypoglykämie, Retinopathie oder Pankreasereignisse
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes Care, online erschienen am 29.03.2025. Verfasst von Matthew M Y Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, U.K. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Hypoglycemic Agents. Die Arbeit wurde bisher 59-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whether benefits extend to both subcutaneous and oral formulations remains unclear. PURPOSE In these meta-analyses, including new data from the Semaglutide cardiOvascular oUtcomes triaL (SOUL) (oral semaglutide) and Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial, we examined cardiovascular (CV) and kidney benefits and risks of long-acting (defined as having pharmacokinetics sufficient to provide 24-h activity) GLP-1RA in T2D. DATA SOURCES A systematic review of PubMed was conducted (to 7 February 2025). STUDY SELECTION Randomized placebo-controlled CV and kidney outcomes trials of GLP-1RA with ≥500 individuals with T2D were included. DATA EXTRACTION A random-effects model was used to estimate hazard ratios (HRs) for MACE, its components, all-cause mortality, hospitalization for heart failure (HHF), a composite kidney outcome (kidney failure [kidney replacement therapy or persistent estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m2], sustained ≥50% eGFR decline or nearest equivalent, or kidney-related death), worsening kidney function, and safety outcomes. DATA SYNTHESIS Across 10 trials (n = 71,351), long-acting GLP-1RA reduced incidence rate of MACE by 14% (HR 0.86 [95% CI 0.81, 0.90]; I2 = 27.6%), HHF by 14% (0.86 [0.79, 0.93]; I2 = 2.1%), and the composite kidney outcome by 17% (0.83 [0.75, 0.92]; I2 = 20.4%) and all-cause mortality by 12% (0.88 [0.82, 0.93]; I2 = 17.5%). A consistent 14% reduction was seen for all MACE components. There was no significant heterogeneity by GLP-1RA administration route (subcutaneous vs. oral). There were no increased risks of severe hypoglycemia, retinopathy, or pancreatic events. LIMITATIONS Trial-level meta-analyses preclude detailed subgroup analyses and may introduce ecological bias. CONCLUSIONS As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, U.K.
- Department of Medicine, Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, OR.
- Institute of Cardiovascular Sciences, University College London, London, U.K.
- Department of Biostatistics, University of Washington, Seattle, WA.
- Section of Endocrinology, Yale School of Medicine, New Haven, CT.
- KfH Kidney Center, Munich, Germany.
ORCID-Profile: Matthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, John Deanfield, Scott S Emerson, Silvio E Inzucchi, Johannes F E Mann, Nikolaus Marx, Sharon L Mulvagh, Neil R Poulter, Sunil V Badve, Richard E Pratley, Vlado Perkovic, John B Buse, Darren K McGuire
Zitieren
APA
Lee, M. M. Y., Sattar, N., Pop-Busui, R., Deanfield, J., Emerson, S. S., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N. R., Badve, S. V., Pratley, R. E., Perkovic, V., Buse, J. B., McGuire, D. K., & SOUL Trial Investigators (2025). Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care. https://doi.org/10.2337/dc25-0241
Vancouver
Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, et al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care. 2025. doi:10.2337/dc25-0241
BibTeX
@article{Lee2025,
author = {Lee, Matthew M Y and Sattar, Naveed and Pop-Busui, Rodica and Deanfield, John and Emerson, Scott S and Inzucchi, Silvio E and Mann, Johannes F E and Marx, Nikolaus and Mulvagh, Sharon L and Poulter, Neil R and Badve, Sunil V and Pratley, Richard E and Perkovic, Vlado and Buse, John B and McGuire, Darren K and SOUL Trial Investigators, SOUL Trial Investigators},
title = {Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials},
journal = {Diabetes Care},
year = {2025},
doi = {10.2337/dc25-0241}
}
EUVIMED